A Randomized, Placebo-Controlled, Double-Blind Phase III Trial Investigating the Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines Using a Stringent Composite Endpoint - Concepedia

Concepedia

Publication | Closed Access

A Randomized, Placebo-Controlled, Double-Blind Phase III Trial Investigating the Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines Using a Stringent Composite Endpoint

59

Citations

16

References

2013

Year

C. William Hanke, Rhoda S. Narins, Fredric S Brandt, Joel L. Cohen, Lisa Donofrio, Jeanine Downie, Moritz Heinz, Laura Harrington, David H. McDaniel, Mark S. Nestor,

Dermatologic Surgery

Abstract

A single dose of 20 U of incobotulinumtoxinA is superior to placebo in the treatment of glabellar frown lines at Day 30 and is well-tolerated.

References

	Year	Citations

Page 1